BVI has received CE marking for Virtuoso®, its first dual-function Phaco-Vitrectomy platform, designed to enhance control, efficiency, and versatility in both cataract and vitreoretinal surgeries. The first patient was successfully treated in December 2025 at LMU Klinikum in Munich, marking a significant milestone for the platform, which was showcased at major industry forums in 2025 and 2026, including EURETINA and ESCRS. The platform’s design emphasizes fluid stability, workflow efficiency, and clinical practice requirements in ophthalmic surgery.

The significance of Virtuoso® lies in its innovative features, such as the proprietary Equality™ fluidic control system, which maintains a constant intraocular pressure (IOP) throughout procedures, and the Resolute™ ultrasound delivery system, which optimizes energy output regardless of lens hardness. These advancements aim to improve surgical outcomes by enhancing control and efficiency during operations. Early clinical evaluations have demonstrated the platform’s ability to stabilize IOP and maintain consistent energy delivery, which are crucial for successful surgical interventions.

The introduction of Virtuoso® could shift current research paradigms by providing a versatile platform that meets the evolving demands of multidisciplinary surgical centers. Its integration into existing workflows may accelerate drug development timelines for ocular therapeutics, as the platform supports both anterior and posterior segment surgeries, potentially leading to more streamlined clinical trials and improved patient outcomes. With commercial availability expected in Q3 2026, Virtuoso® positions BVI as a leader in ophthalmic surgical innovation, reflecting a commitment to meaningful advancements in eye health technology.

Source: globenewswire.com